Table 3.

Comparison of copy number variations (CNVs) between CAISMOV24 cell line and its primary low-grade serous ovarian carcinoma cells

Primary maligant cells						CAISMOV24
Chromosome	CNV	Type	Size (kbp)	Cytoband interval	Gene Count	Chromosome	CNV	Type	Size (kbp)	Cytoband interval	Gene Count
1	1	Gain	221	1p36.32(3,331,773–3,552,456)×3	6	1	3	Gain	113,168 144,332 317,481	1p36.33(2,173,472–2,286,640)×0–1 1p36.33(900,361–1,044,693)×2–3 1p36.32(3,324,208–3,641,689)×0–1	3 8 7
2	1	Gain	242, 771	2p25.3q37.3(12,770–242,783,384)×28–29	1494	2	1	cnLOH	242,76	2p25.3q37.3(15,702–242,775,910) hmz	1494
3	1	Gain	197,79	3p26.3q29(61,891–197,851,986)×3	1279	3	2	Loss Gain	276 197,79	3q12.1(98,596,503–98,872,626)×0–1 3p26.3q29(61,891–197,851,986)×3	1 1278
5	1	Gain	180,606	5p15.33q35.3(113,576–180,719,789)×3	1035	5	1	Gain	180,606	5p15.33q35.3(113,576–180,719,789)×3	1035
6	1	Loss	127	6p25.3(254,282–381,137)×1	1	6	1	Loss	127	6p25.3(254,253–381,137)×1	1
7	3	Gain Gain Gain	7818 66,570 83,982	7q11.21q11.23(66,698,378–74,516,616)×3 7p22.3q11.21(43,360–66,613,020)×3 7q11.23q36.3(75,137,713–159,119,707)×3	58 418 659	7	4	Gain Gain Gain Gain	1695 3221 72,589 80,786	7q11.23(72,692,112–74,386,749)×3 7q11.23q21.11(75,034,632–78,255,196)×3 7p22.3q11.23(43,360–72,632,831)×3 7q21.11q36.3(78,333,779–159,119,707)×3	33 39 436 626
8	4	Loss Gain Gain Gain	140 4398 39,089 99,432	8p11.22(39,247,097–39,386,952)×2 8p11.22p11.1(39,388,765–43,786,723)×4 8p23.3p11.22(158,048–39,246,760)×4 8q11.1q24.3(46,863,521–146,295,771)×4		8	4	Loss Gain Gain Gain	140 4398 39,089 99,432	8p11.22(39,247,097–39,386,952)×1 8p11.22p11.1(39,388,765–43,786,723)×4 8p23.3p11.22(158,048–39,246,760)×4 8q11.1q24.3(46,863,521–146,295,771)×4	2 33 292 511
9	1	Loss	209	9p21.3(21,887,365–22,096,124)×1	4	9	3	Gain Gain Gain	679 3244 21,879	9q34.3(139,282,807–139,961,930)×3 9p21.3(22,086,839–25,330,810)×291–292 9p24.3p21.3(203,861–22,082,884)×2–3	45 5 102
						11	1	Gain	364	11p15.5(241,986–606,294)×3	21
12	4	Gain Gain Gain Gain	9834 11,031 28,314 84,394	12q12q13.12(39,535,139–49,369,195)×29–30 12p13.33p13.2(173,786–11,204,306)×39–40 12p13.2q12(11,207,579–39,521,153)×39–40 12q13.12q24.33(49,385,726–133,777,902)×39–40	68 192 149 778	12	3	Loss Gain Gain	9499 11,276 23,369	12q12q13.11(39,441,095–48,940,506)×1 12p13.33p13.2(173,786–11,450,109)×39–40 12p13.2p11.1(11,466,434–34,835,837)×39–40	51 198 139
13	1	Gain	95,671	13q11q34(19,436,286–115,107,733)×3	459	13	1	Gain	95,671	13q11q34(19,436,286–115,107,733)×3	459
14	1	Gain	86,774	14q11.2q32.33(20,511,672–107,285,437)×2–3	770	14	2	Gain Gain	13,876 71,619	14q32.12q32.33(93,408,967–107,285,437)×29–30 14q11.2q32.12(20,511,672–92,130,966)×29–30	238 521
16	1	cnLOH	90,074	16p13.3q24.3(89,560–90,163,275) hmz	955	16	5	Loss Gain Gain Loss cnLOH	124 143 236 291 82,965	16p13.3(7,094,531–7,218,941)×1 16p13.3(1,986,979–2,129,528)×3 16p13.3(1,052,879–1,288,518)×3 16p13.3(7,441,425–7,732,737)×1 16p13.3q24.3(7,198,476–90,163,275) hmz	1 18 6 1 734
19	1	Gain	1142	19p13.3(260,911–1,403,381)×24–25	51	19	1	Gain	1256	19p13.3(260,911–1,517,292)×24–25	58
20	3	Gain Gain Gain	1499 5355 55,959	20p13(61,568–1,560,550)×3 20q13.32q13.33(57,560,776–62,915,555)×3 20q13.32q13.33(57,560,776–62,915,555)×3	34 106 515	20	3	Gain Gain Gain	557 14,149 47,64	20p12.1(14,319,185–14,875,738)×3 20p13p12.1(61,568–14,210,343)×3 20p12.1q13.33(15,275,354–62,915,555)×3	2 134 518
22	1	Gain	512	22q11.22(22,943,460–23,455,803)×25–26	6	22	1	Gain	458	22q11.22(22,997,802–23,455,803)×24–25	4
X	3	Gain Gain Gain	182 201 384	Xq21.31(88,604,293–88,786,664)×3 Xp22.33(2,956,273–3,156,774)×3 Xq21.2(85,297,084–85,680,929)×3	0 1 2	X	1	Gain	74,778	Xp22.33q13.3(168,546–74,946,70n)×2–3	494

CNV copy number variation; Column “Gene Count” refers to number of genes found in CNV sequence, cnLOH Copy neutral loss of heterozygosity; Cytoband interval based on assembly human genome hg19